Application of ACTL6A gene to preparation of medicine for treating liver cancer or preventing relapse of liver cancer after surgery

A technology for treating and inhibiting liver cancer, applied in gene therapy, drug combination, pharmaceutical formulation, etc., can solve the problems of liver cancer cell invasion and metastasis, cancer cell proliferation, etc., and achieve the goal of increasing the probability of cancer recurrence, improving the quality of life, and preventing the effect of EMT. Effect

Active Publication Date: 2015-09-16
XIANGYA HOSPITAL CENT SOUTH UNIV
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The present invention provides an application of ACTL6A gene in the preparation of drugs for the treatment of liver cancer or postoperative prevention of liver cancer recurrence, so as to solve the technical problem in the prior art that postoperative liver cancer cells in patients with liver cancer are easy to invade and metastasize in the human body, resulting in the spread of cancer cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ACTL6A gene to preparation of medicine for treating liver cancer or preventing relapse of liver cancer after surgery
  • Application of ACTL6A gene to preparation of medicine for treating liver cancer or preventing relapse of liver cancer after surgery
  • Application of ACTL6A gene to preparation of medicine for treating liver cancer or preventing relapse of liver cancer after surgery

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0115] Using lentivirus as the vector, knock out ACTL6A in the plasmid, and then carry out the animal administration process and the results are as follows:

[0116] Hep3B knockout ACTL6A cells and Hep3B control cells were about 5×10 6 After each injection into the subcutaneous tissue of the left groin of nude mice, the obtained results are listed in Figure 7 In A. see Figure 7 Panel A in the middle: subcutaneous tumor formation experiments in nude mice showed that the subcutaneous tumors of Hep3B knockout ACTL6A cells with ACTL6A knockout were significantly smaller than those of Hep3B control cells in the control group. And as Figure 7 A shows that the volume of the subcutaneous tumor formed by the Hep3B knockout ACTL6A cell group is significantly smaller than the volume of the subcutaneous tumor formed by the Hep3B control group. Similar results are obtained after volume measurement and group comparison. The results are listed in Figure 7 in B. see Figure 7 Figure...

Embodiment 2

[0118] After the charge-reversal drug carrier PCL PEI / amide was used as the carrier to carry shACTL6A and then administered to animals, the experimental process and results were as follows:

[0119] The results of liver orthotopic tumor formation experiments were as follows: Figure 8 As shown in Figures A and B, see Figure 8 Panel A in the middle: The picture of liver tumor formation in situ shows that the tumor volume of Hep3B knockout ACTL6A cells in situ is significantly smaller than that of Hep3B control cells in the control group. see Figure 8 In B: The volume difference between the two groups is statistically significant. like Figure 8 A and B show that the liver tumor volume formed by the Hep3B knockout ACTL6A cell group is significantly smaller than the liver tumor formed by the Hep3B control group. Intrahepatic metastases and lung metastases of liver in situ tumor formation were detected, and the rates of liver and lung metastases in the Hep3B knockout ACTL6A ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of the ACTL6A gene to preparation of a medicine for treating liver cancer or preventing relapse of liver cancer after surgery. Experiments show that when corresponding protein coded by the ACTL6A gene is highly expressed in a cell nucleus, the postoperative cancer relapse rate is increased. Through various known dosage methods, the expression of the corresponding protein coded by the ACTL6A gene is restrained. Thus, the EMT function of liver cancer cells in the human body is effectively prevented, the transferring possibility of liver cancer cells in the human body is reduced, survival time of a patient is prolonged after surgery, and transferring and relapse are reduced.

Description

technical field [0001] The invention relates to the field of liver cancer treatment, in particular to the application of an ACTL6A gene in the preparation of drugs for treating liver cancer or preventing recurrence of liver cancer after surgery. Background technique [0002] Hepatocellular Carcinoma (HCC) is a common disease that seriously threatens human life and health. More than 700,000 people die from HCC every year in the world, and the annual new cases in China account for about half of the global total. In recent years, with the advancement of diagnostic methods, surgical techniques and comprehensive treatment methods, more choices have been provided for the diagnosis and treatment of HCC, and the curative effect of HCC has been improved to a certain extent. However, HCC is a kind of tumor with highly malignant biological behavior. It is very easy to invade and metastasize in the early stage. The latter 5-year survival rate hovers around 30%. Therefore, effectively ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K48/00A61P35/00
Inventor 杨连粤肖帅
Owner XIANGYA HOSPITAL CENT SOUTH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap